Publications by authors named "Federico Nichetti"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

1,415

Total Likes

53

Extended Reach

30,785

Social Features

11
T
Thrombin generation predicts early recurrence in breast cancer patients.
Marina Marchetti, Cinzia Giaccherini, Giovanna Masci, Cristina Verzeroli, Laura Russo, Luigi Celio, Roberta Sarmiento, Sara Gamba, Carmen J Tartari, Erika Diani

J Thromb Haemost· September 2020

Videos about Article: user user

2 9

View All Article and Social Media Activity
D
Durvalumab in Advanced Biliary Tract Cancer: Real-World Data From a Large Cohort of Patients Across Multiple International Centers.
Margherita Rimini, Lorenzo Fornaro, Masafumi Ikeda, Oluseyi Abidoye, Jessica Lucchetti, Federico Nichetti

Liver Int· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase III randomized clinical trial of Gemcitabine and Nab-Paclitaxel as switch maintenance versus continuation of modified FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: The PANThEON Study.
Carolina Sciortino, Federico Nichetti, Francesca Bergamo, Federica Palermo, Stefano Tamberi

Dig Liver Dis· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chemotherapy for Locally Advanced Pancreatic Cancer: The Dilemma of David Versus Goliath After NEOPAN.
Federico Nichetti, Letizia Procaccio, Sara Lonardi, Francesca Bergamo

J Clin Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Benchmarking progression-free survival ratio as primary endpoint in precision oncology clinical trials.
Federico Nichetti, Jennifer Hüllein, Pauline du Rusquec, Erin Pleasance, Li Chen

NPJ Precis Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genomic pathway alterations and their prognostic impact in biliary tract cancer: Insights from a multinational cohort treated with cisplatin, gemcitabine, and durvalumab.
Chiara Pirrone, Umberto Malapelle, Francesco Pepe, Federica Lo Prinzi, Federico Nichetti

Eur J Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine, and durvalumab: a large, real-life, worldwide population.
Margherita Rimini, Lorenzo Fornaro, Federica Lo Prinzi, Mario Domenico Rizzato, Anna Saborowski, Federico Nichetti

J Natl Cancer Inst· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validating HER2 copy number variation assessment by NGS: A comparative analysis with immunohistochemistry and in situ hybridization.
Daniele Lorenzini, Rebecca Salvatori, Chiara Costanza Volpi, Desirè Viola Trupia, Monica Niger, Federico Nichetti

Tumori· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Prognostic Index for Advanced Biliary Tract Cancer Treated With Cisplatin, Gemcitabine and Durvalumab: The MAGIC-D Index.
Mara Persano, Margherita Rimini, Francesca Salani, Federica Lo Prinzi, Federico Nichetti

Liver Int· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Outcomes of Molecular Tumor Board Treatment Recommendations.
Federico Nichetti, Marta Brambilla, Matteo Duca, Alberta Piccolo, Daniela Miliziano

JCO Precis Oncol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Prostaglandin EP4 Antagonist Vorbipiprant Combined with PD-1 Blockade for Refractory Microsatellite-Stable Metastatic Colorectal Cancer: A Phase Ib/IIa Trial.
Filippo Pietrantonio, Federica Morano, Monica Niger, Filippo Ghelardi, Claudia Chiodoni, Federico Nichetti

Clin Cancer Res· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early downmodulation of tumor glycolysis predicts response to fasting-mimicking diet in triple-negative breast cancer patients.
Francesca Ligorio, Andrea Vingiani, Tommaso Torelli, Caterina Sposetti, Lorenzo Drufuca, Federico Nichetti

Cell Metab· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Is tumour sequencing effective for the identification of germline pathogenic variant carriers?
Jacopo Azzollini, Iolanda Capone, Matteo Duca, Andrea Vingiani, Alberta Piccolo, Federico Nichetti

Tumori· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular Characterization and Clinical Relevance of MGMT-Silenced Pancreatic Cancer.
Federico Nichetti, Marco Silvestri, Luca Agnelli, Andrea Franza, Chiara Pircher

Cancer Med· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lymphotoxin beta-activated LTBR/NIK/RELB axis drives proliferation in cholangiocarcinoma.
Kaiyu Xu, Annika Kessler, Federico Nichetti, Paula Hoffmeister-Wittmann, Anna-Lena Scherr

Liver Int· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population.
Margherita Rimini, Lorenzo Fornaro, Mario Domenico Rizzato, Lorenzo Antonuzzo, Federico Rossari, Federico Nichetti

Eur J Cancer· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Etiology-independent activation of the LTβ-LTβR-RELB axis drives aggressiveness and predicts poor prognosis in HCC.
Anna-Lena Scherr, Luisa Nader, Kaiyu Xu, Christin Elssner, Dirk A Ridder, Federico Nichetti

Hepatology· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic and predictive impact of sex in locally advanced microsatellite instability high gastric or gastroesophageal junction cancer: An individual patient data pooled analysis of randomized clinical trials.
Alessandra Raimondi, Young Woo Kim, Won Ki Kang, Ruth E Langley, Yoon Young Choi, Federico Nichetti

Eur J Cancer· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study.
Margherita Rimini, Gianluca Masi, Sara Lonardi, Federico Nichetti, Tiziana Pressiani

Target Oncol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY tract cancers (BTC) at high risk for recurrence: PURITY study.
Monica Niger, Federico Nichetti, Lorenzo Fornaro, Chiara Pircher, Federica Morano

BMC Cancer· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence: PURITY study.
Monica Niger, Federico Nichetti, Lorenzo Fornaro, Chiara Pircher, Federica Morano

BMC Cancer· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NALIRIFOX, FOLFIRINOX, and Gemcitabine With Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis.
Federico Nichetti, Simone Rota, Paolo Ambrosini, Chiara Pircher, Eleonora Gusmaroli

JAMA Netw Open· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative Genomic Analysis and Clinical Outcomes of BRAF-mutated Advanced Biliary Tract Cancers.
Tin-Yun Tang, Federico Nichetti, Ben Kaplan, Sara Lonardi, Filippo Pietrantonio

Clin Cancer Res· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Negative hyperselection of elderly patients with RAS and BRAF wild-type metastatic colorectal cancer receiving initial panitumumab plus FOLFOX or 5-FU/LV.
Filippo Pietrantonio, Francesca Bergamo, Daniele Rossini, Filippo Ghelardi, Maria Caterina De Grandis, Federico Nichetti

Eur J Cancer· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and antitumor activity of metformin plus lanreotide in patients with advanced gastro-intestinal or lung neuroendocrine tumors: the phase Ib trial MetNET2.
Sara Pusceddu, Francesca Corti, Natalie Prinzi, Federico Nichetti, Silva Ljevar

J Hematol Oncol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Peripheral blood lymphocytes predict clinical outcomes in hormone receptor-positive HER2-negative advanced breast cancer patients treated with CDK4/6 inhibitors.
Emma Zattarin, Luigi Mariani, Alice Menichetti, Rita Leporati, Leonardo Provenzano, Federico Nichetti

Ther Adv Med Oncol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis